Patents by Inventor David W. Cushman

David W. Cushman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6087368
    Abstract: Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: July 11, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Macor, David P. Rotella, Harold N. Weller, III, David W. Cushman, Joseph P. Yevich
  • Patent number: 5496805
    Abstract: Diuresis, natriuresis, and the lowering of blood pressure are produced in a host by administering one or more neutral endopeptidase inhibitors. An additional blood pressure lowering agent such as an angiotensin converting enzyme inhibitor can be administered along with the neutral endopeptidase inhibitor.
    Type: Grant
    Filed: July 12, 1990
    Date of Patent: March 5, 1996
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Norma G. Delaney, Eric M. Gordon, Jack M. DeForrest, David W. Cushman
  • Patent number: 4474799
    Abstract: The degradation of enkephalins in a mammalian host is inhibited by administration of an enkephalinase enzyme inhibitor of the formula ##STR1##
    Type: Grant
    Filed: May 27, 1983
    Date of Patent: October 2, 1984
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Roland Greenberg, David W. Cushman, B. Richard Vogt, Frank L. Weisenborn, Michael J. Antonaccio
  • Patent number: 4474795
    Abstract: The degradation of enkephalins in a mammalian host is inhibited by administration of an enkephalinase enzyme inhibitor of the formula ##STR1##
    Type: Grant
    Filed: May 27, 1983
    Date of Patent: October 2, 1984
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Roland Greenberg, David W. Cushman, B. Richard Vogt, Frank L. Weisenborn, Michael J. Antonaccio
  • Patent number: 4401677
    Abstract: The degradation of enkephalins in a mammalian host is inhibited by administration of an enkephalinase enzyme inhibitor of the formula ##STR1##
    Type: Grant
    Filed: October 9, 1981
    Date of Patent: August 30, 1983
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Roland Greenberg, David W. Cushman, B. Richard Vogt, Frank L. Weisenborn, Michael J. Antonaccio
  • Patent number: 4339600
    Abstract: Compounds for alleviating or reducing angiotensin related hypertension in hypertensive mammals comprising angiotensin converting enzyme inhibitors selected from a group of mercaptoacyl aminoacids.
    Type: Grant
    Filed: February 13, 1978
    Date of Patent: July 13, 1982
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4228184
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: May 4, 1978
    Date of Patent: October 14, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4207342
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: June 10, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4207336
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: June 10, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4207337
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: June 10, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4206232
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: June 3, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4200649
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: April 29, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4199512
    Abstract: A method for alleviating or reducing angiotensin related hypertension in hypertensive mammals comprises administering to such hypertensive mammals an effective amount of an angiotensin converting enzyme inhibitor selected from a group of mercaptoacyl aminoacids.
    Type: Grant
    Filed: September 18, 1978
    Date of Patent: April 22, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4192882
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors. The compounds claimed in this application are those wherein R.sub.1 is 3-indolyl-lower alkylene.
    Type: Grant
    Filed: May 4, 1978
    Date of Patent: March 11, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4192881
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: March 11, 1980
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4173704
    Abstract: A method for alleviating or reducing angiotensin related hypertension in hypertensive mammals comprises administering to such hypertensive mammals an effective amount of an angiotensin converting enzyme inhibitor selected from a group of mercaptoacyl aminoacids.
    Type: Grant
    Filed: May 26, 1978
    Date of Patent: November 6, 1979
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miquel A. Ondetti, David W. Cushman
  • Patent number: 4154937
    Abstract: New hydroxycarbamoylalkylacyl derivatives of pipecolic acid which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: June 26, 1978
    Date of Patent: May 15, 1979
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: David W. Cushman, Miguel A. Ondetti
  • Patent number: 4154840
    Abstract: New proline derivatives and related compounds which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: March 9, 1978
    Date of Patent: May 15, 1979
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4153725
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: May 4, 1978
    Date of Patent: May 8, 1979
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman
  • Patent number: 4146641
    Abstract: New carboxyalkylacylamino acids which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
    Type: Grant
    Filed: May 4, 1978
    Date of Patent: March 27, 1979
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Miguel A. Ondetti, David W. Cushman